Thalidomide and its derivatives: Emerging from the wilderness

Postgraduate Medical Journal

Volumn 79, Issue 929, 2003, Pages 127-132

  Gordon, J N ^a,b   Goggin, P M ^c  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOKINE; IMMUNOMODULATING AGENT; THALIDOMIDE; THALIDOMIDE DERIVATIVE;

CONSTIPATION; DROWSINESS; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; HUMAN; INFLAMMATION; LIBIDO DISORDER; MALIGNANT NEOPLASTIC DISEASE; MUSCLE WEAKNESS; NERVE FIBER DEGENERATION; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; VERTIGO;

ADJUVANTS, IMMUNOLOGIC; CACHEXIA; CROHN DISEASE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; LEPROSY; NEOPLASMS; ORAL ULCER; RHEUMATIC DISEASES; RISK FACTORS; SKIN DISEASES; THALIDOMIDE;

EID: 0037367899     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.929.127     Document Type: Review

References (77)

1. McBride W. Thalidomide and congenital abnormalities. Lancet 1961;ii:1358.
2. Lenz W. Fragen aus der Praxis: kindliche Missbildungen nach Medikament Einnahme wahrend der Graviditat? Dtsch Med Wochenschr 1961;86:2555-6.
3. Sheskin J. Further observation with thalidomide in lepra reactions. Lepr Rev 1965;36:183-7.
4. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
5. Nishimura K, Hashimoto Y, Iwasaki S. (S)-form of alpha-methyl-N(alpha)- phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects. Chem Pharm Bull (Tokyo) 1994;42:1157-9.
6. Hoglund P, Eriksson T, Bjorkman S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J Pharmacokinet Biopharm 1998;26:363-83.
7. Fabro S, Smith RL, Williams RT. Toxicity and teratogenicity of optical isomers of thalidomide. Nature 1967;215:296.
8. Blaschke G, Kraft H, Fickentscher K, et al. Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers. Arzneimittelforschung 1979;29:1640-2.
9. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001;57:365-76.
10. Trapnell CB, Donahue SR, Collins JM, et al. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther 1998;64:597-602.
11. Teo SK, Harden JL, Burke AB, et al. Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos 2001;29:1355-7.
12. Rowland TL, McHugh SM, Deighton J, et al. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 1998;40:11-20.
13. Rowland TL, McHugh SM, Deighton J, et al. Selective down-regulation of T cell and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone. Immunol Lett 1999;68:325-32.
14. Tavares JL, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997;91:31-9.
15. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;50:196-200.
16. Peterson PK, Hu S, Sheng WS, et al. Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J Infect Dis 1995;172:1137-40.
17. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58(suppl I):1107-13.
18. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;77:1675-80.
19. Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276:22382-7.
20. Shannon EJ, Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells. Immunopharmacol Immunotoxicol 1996;18:59-72.
21. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995;99:160-7.
22. Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997;159:5157-61.
23. Haslett PA, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999;15:1169-79.
24. Dredge K, Marriott JB, Todryk SM, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002;168:4914-19.
25. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
26. Kruse FE, Joussen AM, Rohrschneider K, et al. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998;236:461-6.
27. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8.
28. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6.
29. Oliver SJ, Freeman SL, Corral LG, et al. Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin Exp Immunol 1999;118:315-21.
30. Marriott JB, Westby M, Cookson S, et al. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol 1998;161:4236-43.
31. Iyer CG, Languillon J, Ramanujam K, et al. WHO co-ordinated short-term double- blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 1971;45:719-32.
32. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide. Int J Dermatol 1980;19:318-22.
33. Sampaio EP, Hernandez MO, Carvalho DS, et al. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed Pharmacother 2002;56:13-19.
34. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990;126:923-7.
35. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1487-93.
36. Jacobson JM, Spritzler J, Fox L, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. J Infect Dis 1999;180:61-7.
37. Shek LP, Lim DL. Thalidomide in Behçet's disease. Biomed Pharmacother 2002;56:31-5.
38. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo- controlled trial. Ann Intern Med 1998;128:443-50.
39. Waters MF, Laing AB, Ambikapathy A, et al. Treatment of ulcerative colitis with thalidomide. BMJ 1979;i:792.
40. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999;117:1271-7.
41. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low- dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-87.
42. Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safely and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002;17:135-9.
43. Sabate JM, Villarejo J, Lemann M, et al. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002;16:1117-24.
44. Kaplan G, Thomas S, Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000;16:1345-55.
45. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.
46. Khan ZH, Simpson E, Cole AT, et al. Oesophageal cancer and cachexia: the effects of thalidomide on weight loss and lean body mass in a sequential (metabolic) study. Gut 2002;50(suppl II):A4.
47. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000;60:273-92.
48. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
49. Rajkumar SV, Gertz MA, Kyle RA, et al. Current therapy for multiple myeloma. Mayo Clin Proc 2002;77:813-22.
50. Dmoszynska A, Bojarska-Junak A, Domanski D, et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2002;43:401-6.
51. Neben K, Mytilineos J, Moehler TM, et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 2002;100:2263-5.
52. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-65.
53. Singhal S, Mehta J. Thalidomide in cancer. Biomed Pharmacother 2002;56:4-12.
54. Govindarajan R, Heaton KM, Broodwater R, et al. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000;356:566-7.
55. Bennett C, Schumock G, Desai A, et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 2002;113:603-6.
56. Tseng S, Pak G, Washenik K, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-79.
57. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
58. Vogelsang GB, Hess AD, Santos GW. Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant 1988;3:393-8.
59. Browne PV, Weisdorf DJ, Defor T, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000;26:865-9.
60. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8.
61. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7:265-73.
62. Oliver SJ, Cheng TP, Banquerigo ML, et al. The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumotol 1998;25:964-9.
63. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis-the thalidomide experience. J Rheumotol 1989;16:158-63.
64. Huizinga TW, Dijkmans BA, van der Velde EA, et al. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996;55:833-6.
65. Keesal N, Wasserman MJ, Bookman A, et al. Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol 1999;26:2344-7.
66. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002;122:227-32.
67. Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000;97:109-20.
68. Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997;36:353-9.
69. Hansen JM, Carney EW, Harris C. Differential alteration by thalidomide of the glutathione content of rat vs rabbit conceptuses in vitro. Reprod Toxicol 1999;13:547-54.
70. Newman CG. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol 1986;13:555-73.
71. Neiger BL. The re-emergence of thalidomide: results of a scientific conference. Teratology 2000;62:432-5.
72. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999;5:582-5.
73. Thiele A, Thormann M, Hofmann HJ, et al. A possible role of N-cadherin in thalidomide teratogenicity. Life Sci 2000;67:457-61.
74. Stephens TD, Fillmore BJ. Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology 2000;61:189-95.
75. Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001;24:1050-7.
76. Ochonisky S, Verroust J, Bastuji-Garin S, et al. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994;130:66-9.
77. Powell RJ, Gardner-Medwin JM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994;70:901-4.